Low rate of emergence of nevirapine and lamivudine resistance after post-partum interruption of a triple-drug regimen

Antiviral Therapy

Volumn 13, Issue 1, 2008, Pages 135-139

  Pérez, Héctor ^a   Vignoles, Moira ^b   Laufer, Natalia ^a,b   Gómez, Alejandro ^b   Coll, Patricia ^a   Lattner, Jorge ^a   Rolón, María ^a   Salomón, Horacio ^b   Cahn, Pedro ^a,c  

^a HOSPITAL JUAN A FERNÁNDEZ   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c Huesped Foundation   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINE; CYSTEINE; GUANINE; LAMIVUDINE; LYSINE; METHIONINE; NEVIRAPINE; THYMINE; TYROSINE; VALINE; VIRUS RNA; ZIDOVUDINE;

ADULT; AMINO ACID SEQUENCE; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL ARTICLE; CODON; COMBINATION CHEMOTHERAPY; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABOR; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PUERPERIUM; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; VIRUS LOAD; VIRUS STRAIN; VIRUS TRANSMISSION;

ADULT; ANTI-HIV AGENTS; DISEASE TRANSMISSION, VERTICAL; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MUTATION; NEVIRAPINE; POSTPARTUM PERIOD; PREGNANCY;

EID: 42149172514     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1996; 335:1621-1629.
2. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331:1173-1180.
3. World Health Organization. Antiretroviral therapy of HIV infection in infants and children in resource-limited settings: towards universal access. Geneva: WHO 2006; pp 151.
4. Dabis F, Bequet L, Ekouevi DK, et al. Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission. AIDS 2005; 19:309-318.
5. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354:795-802.
6. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001; 15:1951-1957.
7. Eshleman SH, Jackson JB. Nevirapine resistance after single dose prophylaxis. AIDS Rev 2002; 4:59-63.
8. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 2004; 351:229-240.
9. Flys TS, Nissley DV, Claasen CW, et al. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis 2005; 192:24-29.
10. Flys TS, Donnell D, Mwatha A, et al. Persistence of K103N-Containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission. J Infect Dis 2007; 195:711-715.
11. Giaquinto C, Rampon O, De Rossi A. Antiretroviral therapy for prevention of mother-to-child HIV transmission: focus on single-dose nevirapine. Clin Drug Investig 2006; 26:611-627.
12. Lyons FE, Coughlan S, Byrne CM, Hopkins SM, Hall WW, Mulcahy FM. Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy. AIDS 2005; 19:63-67.
13. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002; 29:484-494.
14. Sociedad Argentina de Infectología. Primer Consenso Argentino de Terapia Antirretroviral 2006 (Updated 26 November 2006. Accessed 13 December 2007). Available from http://www.sadi.org.ar/images/CONSENSOTAARV2006.pdf
15. Gomez-Carrillo M, Quarleri JF, Rubio AE, et al. Drug resistance testing provides evidence of the globalization of HIV type 1: a new circulating recombinant form. AIDS Res Hum Retroviruses 2004; 20:885-888.
16. Stanford University. Genotypic Resistance Interpretation Algorithm (accessed 13 December 2007). Available from: http://hivdb6.stanford.edu/asi/ deployed/hiv_central.pl?program=hivdb&action=showSequenceForm.
17. Lole KS, Bollinger RC, Paranjape RS, et al. Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol 1999;73:152-160.
18. Lecossier D, Shulman NS, Morand-Joubert L, et al. Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine. J Acquir Immune Defic Syndr 2005; 38:37-42.
19. Johnson JA, Li JF, Morris L, et al. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis 2005; 192:16-23.
20. Bergroth T, Sonnerborg A, Yun Z. Discrimination of lamivudine resistant minor HIV-1 variants by selective real-time PCR. J Virol Methods 2005; 127:100-107.
21. Gomez-Carrillo M, Pampuro S, Duran A, et al. Analysis of HIV type 1 diversity in pregnant women from four Latin American and Caribbean countries. AIDS Res Hum Retroviruses 2006; 22:1186-1191.
22. Aulicino PC, Holmes EC, Rocco C, et al. Extremely rapid spread of human immunodeficiency virus type 1 BF recombinants in Argentina. J Virol 2007; 81:427-429.
23. Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007; 356:135-147.
24. Eshleman SH, Hoover DR, Chen S, et al. Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. AIDS 2005; 19:2167-2169.